Skip to main content

A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions

Abstract

Purpose

To review the literature for outcome measures for oral viral infections in cancer patients. A secondary aim was to update the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines for the management of oral viral infections in cancer patients.

Methods

Databases were searched for articles published in the English language, 1981–2013. Studies that met the eligibility criteria were reviewed systematically. The data about the outcome measures were classified according to the aim of the study: prevention, treatment, or non-interventional. The results of interventional studies were compared to the 2010 MASCC/ISOO publication.

Results

Multiple clinical and laboratory tests were used to measure oral viral infections, with great variability between studies. Most of the studies were about Herpes Simplex Virus (HSV). The outcome measure that was most commonly used was the presence of HSV infection diagnosed based on a combination of suggestive clinical presentation with a positive laboratory result. HSV culture was the most commonly reported laboratory outcome measure. Acyclovir and valacyclovir were consistently reported to be efficacious in the management of oral herpetic infections. No new data on the quality of life and economic aspects was found.

Conclusions

Considering the variability in outcome measures reported to assess oral herpetic infections the researcher should select carefully the appropriate measures based on the objective of the study. Acyclovir and valacyclovir are effective in the management of oral herpetic infections in patients receiving treatment for cancer. Studies on newer anti-viral drugs may be useful to address the issue of anti-viral resistance.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Chen YK, Hou HA, Chow JM, Chen YC, Hsueh PR, Tien HF (2011) The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. European journal of clinical microbiology & infectious diseases 30(6):753–759. doi:10.1007/s10096-010-1148-z

  2. Ruping MJ, Keulertz C, Vehreschild JJ, Lovenich H, Sohngen D, Wieland U, Cornely OA (2011) Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. Support. Care Cancer 19(8):1211–1216. doi:10.1007/s00520-010-0940-8

  3. Sepulveda E, Brethauer U, Rojas J, Fernandez E, Le Fort P (2005) Oral ulcers in children under chemotherapy: clinical characteristics and their relation with herpes simplex virus type 1 and Candida albicans. Med. Oral Patol. Cir. Bucal. 10(Suppl 1):E1–E8

  4. Saral R (1990) Oral complications of cancer therapies. Management of acute viral infections. NCI Monogr. 9:107–110

  5. Schubert MM, Peterson DE, Flournoy N, Meyers JD, Truelove EL (1990) Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection. Oral Surg. Oral Med. and Oral Pathol. 70(3):286–293

  6. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012

    CAS  Article  PubMed  Google Scholar 

  7. Elad S, Zadik Y, Hewson I, Hovan A, Correa ME, Logan R, Elting LS, Spijkervet FK, Brennan MT (2010) A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Support. Care Cancer 18(8):993–1006. doi:10.1007/s00520-010-0900-3

  8. Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49(7):749–754

    CAS  Article  PubMed  Google Scholar 

  9. Somerfield M, Padberg J, Pfister D, Bennett C, Recht A, Smith T, Weeks J, Winn R, Durant J (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments 4(4):881–886

    Google Scholar 

  10. Anderson H, Scarffe JH, Sutton RN, Hickmott E, Brigden D, Burke C (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer 50(1):45–49

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J (1995) Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ (Clinical research ed) 310(6988):1169–1172

    CAS  Article  Google Scholar 

  12. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J (1997) Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 15(6):2269–2274

  13. Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura SI, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y (2013) Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 15(5):457–465. doi:10.1111/tid.12118

  14. Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM (2001) Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Med. Oral 6(5):326–334

  15. Bergmann OJ, Mogensen SC, Ellegaard J (1990) Herpes simplex virus and intraoral ulcers in immunocompromised patients with haematologic malignancies. European journal of clinical microbiology & infectious diseases 9(3):184–190

  16. Chandrasekar PH, Abraham OC, Klein J, Alangaden G, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R (2001) Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin. Infect. Dis. 32(4):546–551. doi:10.1086/318715

  17. Djuric M, Jankovic L, Jovanovic T, Pavlica D, Brkic S, Knezevic A, Markovic D, Milasin J (2009) Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J. Oral Pathol. Med. 38(2):167–173. doi:10.1111/j.1600-0714.2008.00684.x

  18. Gomez RS, Carneiro MA, Souza LN, Victoria JM, de Azevedo WM, De Marco L, Kalapothakis E (2001) Oral recurrent human herpes virus infection and bone marrow transplantation survival. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 91(5):552–556. doi:10.1067/moe.2001.112568

  19. Lloid ME, Schubert MM, Myerson D, Bowden R, Meyers JD, Hackman RC (1994) Cytomegalovirus infection of the tongue following marrow transplantation. Bone Marrow Transplant 14(1):99–104

    CAS  PubMed  Google Scholar 

  20. Redding SW, Luce EB, Boren MW (1990) Oral herpes simplex virus infection in patients receiving head and neck radiation. Oral Surg. Oral Med. Oral Pathol. 69(5):578–580

  21. Beattie G, Whelan J, Cassidy J, Milne L, Burns S, Leonard R (1989) Herpes simplex virus, Candida albicans and mouth ulcers in neutropenic patients with non-haematological malignancy. Cancer Chemother Pharmacol 25(1):75–76

    CAS  Article  PubMed  Google Scholar 

  22. Epstein JB, Gorsky M, Hancock P, Peters N, Sherlock CH (2002) The prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 94(6):712–716. doi:10.1067/moe.2002.127585

  23. Guimaraes AL, Gomes CC, da Silva LM, Correia-Silva Jde F, Victoria JM, Gomez RS, Bittencourt H (2009) Association between oral HSV-1 and survival in allogeneic hematopoietic stem cell transplanted patients. Med. Oral Patol. Oral Cir. Bucal. 14(2):E62–E68

  24. Dreizen S, Bodey GP, Valdivieso M (1983) Chemotherapy-associated oral infections in adults with solid tumors. Oral Surg. Oral Med. Oral Pathol. 55(2):113–120

  25. Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, Dardoufas K, Polychronopoulou AP, Athanassiadou P, Kolitsi G, Kouvaris J (2011) Oral mucositis, pain and xerostomia in 135 head and neck cancer patients receiving radiotherapy with or without chemotherapy. The Open Cancer Journal 4 (1)

  26. Ramirez-Amador V, Esquivel-Pedraza L, Mohar A, Reynoso-Gomez E, Volkow-Fernandez P, Guarner J, Sanchez-Mejorada G (1996) Chemotherapy-associated oral mucosal lesions in patients with leukaemia or lymphoma. Eur J Cancer B Oral Oncol 32b(5):322–327

    CAS  Article  PubMed  Google Scholar 

  27. Barrett AP (1986) A long-term prospective clinical study of orofacial herpes simplex virus infection in acute leukemia. Oral Surg. Oral Med. Oral Pathol. 61(2):149–152

  28. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M (2003) Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 31(1):51–55. doi:10.1038/sj.bmt.1703817

    CAS  Article  PubMed  Google Scholar 

  29. Engelhard D, Morag A, Or R, Naparstek E, Cividalli G, Ruchlemer R, Aker M, Maayan S, Slavin S (1988) Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts. Isr J Med Sci 24(3):145–150

    CAS  PubMed  Google Scholar 

  30. Epstein JB, Sherlock C, Page JL, Spinelli J, Phillips G (1990) Clinical study of herpes simplex virus infection in leukemia. Oral Surg. Oral Med. Oral Pathol. 70(1):38–43

  31. Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB (2004) Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk. Lymphoma 45(11):2215–2219. doi:10.1080/10428190410001733763

  32. Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ, Lietman PS (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99(6):773–776

    CAS  Article  PubMed  Google Scholar 

  33. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305(2):63–67. doi:10.1056/nejm198107093050202

    CAS  Article  PubMed  Google Scholar 

  34. Shepp DH, Dandliker PS, Flournoy N, Meyers JD (1987) Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 43(5):654–658

    CAS  Article  PubMed  Google Scholar 

  35. Warkentin DI, Epstein JB, Campbell LM, Yip JG, Cox VC, Ransier A, Barnett MJ, Marra F (2002) Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother 36(10):1525–1531

    CAS  Article  PubMed  Google Scholar 

  36. Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, Mazeron MC, Perol Y (1983) Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J Antimicrob Chemother 12(Suppl B):161–167

    Article  PubMed  Google Scholar 

  37. Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D (2002) Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol. Blood Marrow Transplant. 8(12):662–665

  38. Wade JC, Newton B, Flournoy N, Meyers JD (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100(6):823–828

    CAS  Article  PubMed  Google Scholar 

  39. Carrega G, Castagnola E, Canessa A, Argenta P, Haupt R, Dini G, Garaventa A (1994) Herpes simplex virus and oral mucositis in children with cancer. Support. Care Cancer 2(4):266–269

  40. Shepp DH, Newton BA, Dandliker PS, Flournoy N, Meyers JD (1985) Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 102(6):783–785

    CAS  Article  PubMed  Google Scholar 

  41. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 96(3):265–269

    CAS  Article  PubMed  Google Scholar 

  42. Mitchell CD, Bean B, Gentry SR, Groth KE, Boen JR, Balfour HH Jr (1981) Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet (London, England) 1(8235):1389–1392

    CAS  Article  Google Scholar 

  43. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, Sotiropoulou-Lontou A, Dardoufas K, Polychronopoulou A, Gonidi M, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanikolaou IS, Kouvaris J (2006) Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support. Care Cancer 14(7):753–762. doi:10.1007/s00520-005-0006-5

  44. Nicolatou-Galitis O, Dardoufas K, Markoulatos P, Sotiropoulou-Lontou A, Kyprianou K, Kolitsi G, Pissakas G, Skarleas C, Kouloulias V, Papanicolaou V, Legakis NJ, Velegraki A (2001) Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J. Oral Pathol. Med. 30(8):471–480

  45. Tricot G, De Clercq E, Boogaerts MA, Verwilghen RL (1986) Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J Med Virol 18(1):11–20

    CAS  Article  PubMed  Google Scholar 

  46. Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE, Burke C, Crawford DH, Brumfitt W, Hoffbrand AV (1983) Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 287(6389):384–388

    CAS  Article  Google Scholar 

  47. van der Beek MT, Laheij AM, Raber-Durlacher JE, von dem Borne PA, Wolterbeek R, van der Blij-de Brouwer CS, van Loveren C, Claas EC, Kroes AC, de Soet JJ, Vossen AC (2012) Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 47(9):1222–1228. doi:10.1038/bmt.2012.2

    Article  PubMed  Google Scholar 

  48. Appendices (2009). Bone marrow transplantation 44 (8):527–536

  49. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 44(8):453–455. doi:10.1038/bmt.2009.254

  50. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P, McDonald GB, Hirsch H (2009) Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 44(8):471–482

    CAS  Article  PubMed  Google Scholar 

  51. Kim JH, Schaenman JM, Ho DY, Brown JM (2011) Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol. Blood Marrow Transplant. 17(2):259–264. doi:10.1016/j.bbmt.2010.06.020

  52. Varella RB, Guimaraes MA, Guimaraes AC, Atalla A, Nucci M, Ramos-e-Silva M (2012) Acyclovir susceptibility of herpes simplex virus isolates from transplanted and nontransplanted patients in Rio de Janeiro, Brazil. Skinmed 10(4):208–211

    PubMed  Google Scholar 

  53. Andrei G, Georgala A, Topalis D, Fiten P, Aoun M, Opdenakker G, Snoeck R (2013) Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J. Infect. Dis. 207(8):1295–1305. doi:10.1093/infdis/jit019

  54. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D (2003) Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16(1):114–128

  55. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M (2007) Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J. Infect. Dis. 196(2):266–270. doi:10.1086/518938

  56. Nichols WG, Boeckh M, Carter RA, Wald A, Corey L (2003) Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. J. Infect. Dis. 187(5):801–808. doi:10.1086/367894

  57. Langston AA, Redei I, Caliendo AM, Somani J, Hutcherson D, Lonial S, Bucur S, Cherry J, Allen A, Waller EK (2002) Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 99(3):1085–1088

    CAS  Article  PubMed  Google Scholar 

  58. Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, Hamprecht K (2000) Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96(9):3286–3289

    CAS  PubMed  Google Scholar 

  59. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99(4):1159–1164

    CAS  Article  PubMed  Google Scholar 

  60. Cesaro S, Zhou X, Manzardo C, Buonfrate D, Cusinato R, Tridello G, Mengoli C, Palu G, Messina C (2005) Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J. Clin. Virol. 34(2):129–132. doi:10.1016/j.jcv.2005.02.009

  61. Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U, Plettig R, Geissler G, Rethwilm A, Ehninger G, Bornhauser M (2001) Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71(7):880–885

    CAS  Article  PubMed  Google Scholar 

  62. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, Ullmann J, Musso M, Trenschel R, Ribaud P, Bornhauser M, Cesaro S, Crooks B, Dekker A, Gratecos N, Klingebiel T, Tagliaferri E, Ullmann AJ, Wacker P, Cordonnier C (2001) Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working Party of the European Group for blood and marrow transplantation. Blood 97(2):388–392

    CAS  Article  PubMed  Google Scholar 

  63. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH (2010) 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 54(11):4714–4722. doi:10.1128/aac.00974-10

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Mommeja-Marin H, Boeckh M (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369(13):1227–1236. doi:10.1056/NEJMoa1303688

    CAS  Article  PubMed  Google Scholar 

  65. Whitley RJ, Prichard M (2014) A novel potential therapy for HSV. N Engl J Med 370(3):273–274. doi:10.1056/NEJMe1313982

    CAS  Article  PubMed  Google Scholar 

  66. Vere Hodge RA, Field HJ (2013) Antiviral agents for herpes simplex virus. Adv. Pharmacol. (San Diego, Calif) 67:1–38. doi:10.1016/b978-0-12-405880-4.00001-9

Download references

Acknowledgment

The authors would like to thank Doug Peterson, DMD PhD FDS RCSEd, Oral Health and Diagnostic Sciences, Uconn Health, for reviewing this paper and providing valuable guidance. Additionally, the authors would like to thank Girija Naidu, DDS, Advanced Education in General Dentistry Program, General Dentistry, Eastman Institute for Oral Health, Rochester, NY for her assistance with the early data compilation.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Sharon Elad.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

No sources of funding.

Electronic supplementary material

ESM 1

(DOCX 164 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Elad, S., Ranna, V., Ariyawardana, A. et al. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer 25, 687–700 (2017). https://doi.org/10.1007/s00520-016-3477-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-016-3477-7

Keywords

  • Oral viral infection
  • Outcome measures
  • Efficacy of intervention
  • Herpes virus
  • HSV
  • Cancer